343 related articles for article (PubMed ID: 23979750)
1. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.
Sutcliffe JA; O'Brien W; Fyfe C; Grossman TH
Antimicrob Agents Chemother; 2013 Nov; 57(11):5548-58. PubMed ID: 23979750
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015.
Zhanel GG; Baxter MR; Adam HJ; Sutcliffe J; Karlowsky JA
Diagn Microbiol Infect Dis; 2018 May; 91(1):55-62. PubMed ID: 29338931
[TBL] [Abstract][Full Text] [Related]
3. Eravacycline, a newly approved fluorocycline.
Lee YR; Burton CE
Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1787-1794. PubMed ID: 31175478
[TBL] [Abstract][Full Text] [Related]
4. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent.
Zhanel GG; Cheung D; Adam H; Zelenitsky S; Golden A; Schweizer F; Gorityala B; Lagacé-Wiens PR; Walkty A; Gin AS; Hoban DJ; Karlowsky JA
Drugs; 2016 Apr; 76(5):567-88. PubMed ID: 26863149
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.
Karlowsky JA; Adam HJ; Baxter MR; Lagacé-Wiens PR; Walkty AJ; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2013 Nov; 57(11):5600-11. PubMed ID: 23979759
[TBL] [Abstract][Full Text] [Related]
6. Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent.
Zhanel GG; Esquivel J; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Hink R; Berry L; Schweizer F; Zhanel MA; Bay D; Lagacé-Wiens PRS; Walkty AJ; Lynch JP; Karlowsky JA
Drugs; 2020 Feb; 80(3):285-313. PubMed ID: 31970713
[TBL] [Abstract][Full Text] [Related]
7. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.
Petraitis V; Petraitiene R; Maung BBW; Khan F; Alisauskaite I; Olesky M; Newman J; Mutlib A; Niu X; Satlin M; Singh RS; Derendorf H; Walsh TJ
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29941646
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
[TBL] [Abstract][Full Text] [Related]
10. Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.
Monogue ML; Thabit AK; Hamada Y; Nicolau DP
Antimicrob Agents Chemother; 2016 Aug; 60(8):5001-5. PubMed ID: 27353265
[TBL] [Abstract][Full Text] [Related]
11.
Morrissey I; Hawser S; Lob SH; Karlowsky JA; Bassetti M; Corey GR; Olesky M; Newman J; Fyfe C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843997
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Bouchillon SK; Hoban DJ; Johnson BM; Johnson JL; Hsiung A; Dowzicky MJ;
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):173-9. PubMed ID: 16105561
[TBL] [Abstract][Full Text] [Related]
13. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications.
Huang PY; Hsu CK; Tang HJ; Lai CC
Expert Rev Anti Infect Ther; 2024 Jun; 22(6):387-398. PubMed ID: 38703093
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: A clinical microbiological study.
Tsai MH; Chen CL; Chang HJ; Chuang TC; Chiu CH
J Glob Antimicrob Resist; 2024 Jun; 37():93-99. PubMed ID: 38552878
[TBL] [Abstract][Full Text] [Related]
15.
Morrissey I; Olesky M; Hawser S; Lob SH; Karlowsky JA; Corey GR; Bassetti M; Fyfe C
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31843999
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the
Snydman DR; McDermott LA; Jacobus NV; Kerstein K; Grossman TH; Sutcliffe JA
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29483114
[TBL] [Abstract][Full Text] [Related]
17. Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent.
Xiao XY; Hunt DK; Zhou J; Clark RB; Dunwoody N; Fyfe C; Grossman TH; O'Brien WJ; Plamondon L; Rönn M; Sun C; Zhang WY; Sutcliffe JA
J Med Chem; 2012 Jan; 55(2):597-605. PubMed ID: 22148514
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.
Zhang Y; Lin X; Bush K
J Antibiot (Tokyo); 2016 Aug; 69(8):600-4. PubMed ID: 27353166
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
